---
title: "When billed and allowed amounts aren’t enough: HealthVerity market cost offering in taXonomy"
description: Learn why billed and allowed amounts fall short in claims data and how taXonomy Market Costs deliver consistent, reliable healthcare cost insights.
image: https://blog.healthverity.com/hubfs/when-billed-and-allowed-amounts-arent-enough-featured.png
---
Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/)
- [Contact](https://healthverity.com/contact/)
- [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/)
[](https://healthverity.com/)
- How We Help
- Featured Content
- [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
- [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
- Data Ecosystem
- [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
- [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
- [Precision Event Alerts](https://healthverity.com/precision-event-alerts/)
- [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/)
- [Media Measurement](https://healthverity.com/media-measurement/)
- [Insurance Underwriting](https://healthverity.com/insurance-underwriting/)
- Technology Products
- [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
- [HealthVerity FLOW](https://healthverity.com/flow/portal/)
- [Governance Manager](https://healthverity.com/governance-manager/)
- [Smart Contracts](https://healthverity.com/smart-contracts-manager/)
- Symphony
- Symphony Health Platform
- [Symphony Health Overview](https://healthverity.com/symphony-health/overview/)
- [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- Symphony Solutions
- [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/)
- [HealthRankings](https://healthverity.com/symphony-health/health-rankings/)
- [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/)
- [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/)
- [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/)
- Symphony Products
- [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf)
- [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf)
- [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf)
- [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf)
- [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf)
- [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf)
- [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf)
- [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf)
- Symphony Technology
- [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf)
- [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/)
- Who We Serve
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Government](https://healthverity.com/government/)
- [Insurance](https://healthverity.com/insurance/)
- [Channel Partners](https://healthverity.com/channel-partners/)
- [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
- Resources
- [HealthVerity Blog](https://blog.healthverity.com/)
- [News & Events](https://healthverity.com/resources/news-and-events/)
- [Resource Library](https://healthverity.com/resources/resource-library/)
- [Publications](https://healthverity.com/resources/publications/)
- [The IPGE Approach](https://healthverity.com/ipge-approach/)
- [Zombie Data Explained](https://healthverity.com/get-verified/)
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)
[Request Demo](https://healthverity.com/request-demo/)
[Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/)
[](https://healthverity.com/)
- How We Help
- Symphony
- Who We Serve
- Resources
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)
[Request Demo](https://healthverity.com/request-demo/)
Featured Content
###### HealthVerity MarketplaceTM
The nation’s largest healthcare and consumer data ecosystem
###### taXonomy Pathways
Unique features per therapeutic area with claims, labs and EHR including notes
###### HealthVerity eXOs
AI-native real-world evidence generation
###### Identity Manager (HVID)
Standalone de-identification as a service
Data Ecosystem
HealthVerity MarketplaceTM
HealthVerity TaxonomySM
HealthVerity Notes
Precision Event Alerts
HealthVerity Mastersets
Media Measurement
Syndicated Audiences
Insurance Underwriting
Technology Products
Identity Manager (HVID)
HealthVerity for Clinical Trial Linkage
HealthVerity for Commercial
Smart Contracts
HealthVerity for Registries
Symphony Health Platform
###### Symphony Health Overview
Seamless Data. Stronger Insights. Smarter Decisions.
###### Integrated Dataverse
Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view.
###### Symphony HealthCloud
Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud.
Symphony Solutions
Health technology and business intelligence solutions
Integrated Dataverse and Source Solutions
Brand strategy and sales
HealthRankings
Market access
Patient Journey
Medicines affordability
Symphony Products
PayerSource®
PrescriberSource®
PatientSource®
PatientSourceCompleteTM
PatientSourceDUOTM
Symphony FLEXTM
CustomerSource®
DiagnosticSource®
NonRetailSource®
Symphony Technology
Symphony HealthCloud
Synoma Data Integration
Vantage Applications
Metys
###### Life Sciences
Technology solutions from development through commercialization
###### Channel Partners
HealthVerity enables partners to unlock unprecedented value and insights for clients
###### Government
Comprehensive and compliant solutions to manage the nation’s care
###### Data Ecosystem Partners
Join the nation’s largest data partner ecosystem
###### Insurance
Insurance-grade solutions that excel in managing risk and rebates
###### HealthVerity Blog
Insights and updates from industry experts
###### Publications
Peer-reviewed research and discoveries
###### News & Events
Stay informed about our latest announcements and happenings
###### The IPGE Approach
Fundamentals that power everything that we do and every solution we offer
###### Resource Library
Explore guides, webinars, and tools to enhance your understanding
###### Zombie Data Explained
Learn how data quality drives better research outcomes
[Thought Leadership](https://blog.healthverity.com/tag/thought-leadership), [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices), [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims)
# When billed and allowed amounts aren’t enough: HealthVerity market cost offering in taXonomy
[By \- John Cosenza,](https://blog.healthverity.com/author/john-cosenza) April 22, 2026
## 
## A better way to measure healthcare costs in closed claims data
This is the second post in our four-part [taXonomy](https://healthverity.com/taxonomy/) X blog series ([part 1 here](https://blog.healthverity.com/inside-taxonomy-a-next-gen-closed-claims-solution-for-real-world-evidence-generation)), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, we’ll discuss why traditional allowed and billed amounts can be incomplete or inconsistent, and how taXonomy’s Market Costs offering addresses these limitations by offering a more consistent, validated, and study-ready cost signal to support high-quality real-world evidence (RWE) generation.
Accurately quantifying the costs of services and therapies has become an increasingly critical endpoint in RWE studies. However, in closed claims, “costs” are often oversimplified especially when billed or payer allowed amounts are used as a proxy and assumed to be complete and broadly representative.
In real-world data (RWD), payer-allowed and billed amounts may be missing, obfuscated or unevenly distributed, and closed claims datasets can be concentrated to specific insurance plans or payer types, both of which can limit generalizability in cost-focused studies. Even when allowed or billed amounts are present, the cost details and what they represent are often inconsistent across suppliers, making it challenging to establish normalization and ensure accurate comparability. Further, some sources may offer more granular cost metrics (e.g., separating payer-paid and patient-paid components such as deductibles and copays), while others may offer only a single rolled-up amount, further exacerbating the challenges of accurately applying these values to cost-based use cases.
Heterogeneity in supplier cost fields is a well-established limitation. When present in closed claims, it extends beyond simple missingness. This can bias conclusions, constrain study feasibility and reproducibility, and complicate comparisons across cohorts and markets.
These known challenges inspired HealthVerity to develop [taXonomy’s](https://healthverity.com/taxonomy/) Market Costs offering: a novel, proprietary methodology that generates consistent, accurate, and standardized cost values, addressing gaps in incomplete or heterogeneous supplier cost fields.
## How taXonomy market costs work
### Medical Market Costs (835 remittance-based):
For medical services, HealthVerity Medical Market Costs are built from raw remittance data captured on Electronic Remittance Advice (ERA) 835 forms. The data on these forms document the *actual payment exchange* among patients, payers, and providers. Because the 835 remittance form includes very detailed payment details and adjustments, it enables the creation of standardized allowed amounts, payer paid, and patient paid benchmarks at the individual procedure code level.
HealthVerity aggregates these transactional values into unit-cost benchmarks that are categorized at a highly granular level via a unique combination of procedure code, procedure modifier(s), revenue code(s), units billed, payer type, U.S. Census region, and calendar year. The distribution of these values is provided for every unique combination of these fields, granting researchers the ability to isolate factors that most directly influence reimbursement within a given region and/or across payer types, for example. National level benchmarks are also readily available when this level of granularity is not required.
### Pharmacy Market Costs (open pharmacy claims-based):
For prescriptions, taXonomy Pharmacy Market Costs are built from open pharmacy claims, which reflect the *real-world adjudication and payment* dynamics occurring between payers and pharmacies for dispensed prescriptions.
Pharmacy benchmarking is built at the “base product key” level, which captures a product configuration inclusive of name, form, strength, quantity dispensed, and generic indicator. Similarly, a base product key’s cost is captured across every unique combination of quantity dispensed, payer type, U.S. Census region, and calendar year. These benchmarks are then used to populate market cost fields on prescription records including allowed amount as well as plan-vs-patient paid components.
## Putting taXonomy market costs to the test
In our recently-accepted [ISPOR 2026 abstract](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-3-3/do-data-sources-matter-comparing-market-cost-and-payer-cost-approaches-to-calculating-medical-spending-measures-in-real-world-data), we evaluated whether integrating 835 remittance data and open pharmacy claims improves the generalizability of cost estimates.
Specifically, payer cost was defined as the allowed amount captured in closed claims, while market cost applied closed-claims utilization to a median unit cost benchmark stratified by service type, payer, geography, and time period.
A key question is whether market-based estimates reproduce the same spending signal observed using payer costs when available. To assess this, we evaluated the concordance between market and payer cost estimates by calculating total annual direct medical spending among taXonomy patients with continuous commercial medical and pharmacy enrollment throughout calendar year 2024, restricted to individuals with both cost measures available.Using statistical techniques commonly used in clinical agreement studies, we evaluated alignment between the two measures using linear regression and the Equivariant Passing–Bablok method to estimate translation between measures.
## What we found
The validation exercise used a random sample of **10,409,060** continuously-enrolled commercially insured individuals with both sets of costs available. The results showed strong alignment overall. Linear regression produced a slope of **0.996** (95% CI: **0.982–1.01**), indicating accurate prediction of payer-derived spending from market-derived spending. Passing–Bablok produced a slope of **0.956** (0.944–0.968), providing a translation from market-derived to payer-derived spending, the inverse of which can be used to translate from payer-derived to market-derived spending.
The overall conclusion is clear. Market-derived spending demonstrates strong agreement with payer-derived spending at the person-year level, supporting market cost measures as an appropriate proxy for payer costs in RWE studies.
## Why this matters
This expands what’s feasible for cost-based analyses using closed claims data. Rather than restricting analyses only to segments where payer allowed amounts are fully populated, or dropping records when allowed is missing or obfuscated, market costs provide a standardized alternative that tracks closely with payer-derived spending.
In turn, the [taXonomy](https://healthverity.com/taxonomy/) Market Cost methodology supports high quality RWE generation for life sciences organizations and the researchers working on their behalf by making cost measurements more comprehensive and consistent, resulting in improved study design and findings that are more reliable and generalizable across markets, greater reproducibility, and enhanced robustness to variability in payer-cost completeness.
## [](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKg5ArVplcnMUqksKD4nMelATc6SACN0DmCpHrAFOKwH8dkCE67KdjnvsE3hG0QcY4c0k9d5T1Q7pdvI0QciCtDb7GSWlS2aCwgR8SIshTwy1uSTkz3hUYsCZ783yT7iVqJ61dThDtZaiKtNi3nTvP02CY1T7VIuBUYGH9r0koudS7faGiTYjIqPuHy2lYPx0NNLiZPoJqLdJVxumudB6eM%2FCo7HMW5GC6Q&webInteractiveContentId=188589266814&portalId=5412465)
[](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIn1BJ5VvuPmn7Ug%2FFhILCDaAx2VH0spO6bYczlWddvKHZJ9ZwkkeZHPAAVrvXicQ7ehrC9uogxbqGJEuDqIHDqtQF3%2FAifsaAcHJJMXpT7bvSv0Ux%2FvLipZnGWCkZdDGU3lJoLqVXOsddup8Pq7oHQERqDcXrehWPEeoSnhl9jqkbToT2QZrIBQiSat5Xrqeg7cc1T3gi8&webInteractiveContentId=209041299597&portalId=5412465)
###### Category
- [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices)
- [Trends & Insights](https://blog.healthverity.com/tag/trends-insights)
- [HEOR](https://blog.healthverity.com/tag/heor)
- [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd)
- [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership)
- [Industry Updates](https://blog.healthverity.com/tag/industry-updates)
- [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims)
- [Case Studies](https://blog.healthverity.com/tag/case-studies)
- [Commercial Pharma](https://blog.healthverity.com/tag/commercial-pharma)
- [Government](https://blog.healthverity.com/tag/government)
- [AI](https://blog.healthverity.com/tag/ai)
- [eXOs](https://blog.healthverity.com/tag/exos)
- [Audiences](https://blog.healthverity.com/tag/audiences)
- [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways)
- [Clinical Notes](https://blog.healthverity.com/tag/clinical-notes)
- [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases)
###### Popular Post
- [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals)
- [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies)
- [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims)
- [An integrated approach for deeper insight with both open and closed claims data](https://blog.healthverity.com/an-integrated-approach-for-deeper-insight-with-both-open-and-closed-claims-data)
- [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)
###### Subscribe
### Similar Blogs
[](https://blog.healthverity.com/top-ways-to-close-the-evidence-gap-before-year-end-taxonomy-pathways)
#### [Top ways to close the evidence gap before year end: taXonomy Pathways](https://blog.healthverity.com/top-ways-to-close-the-evidence-gap-before-year-end-taxonomy-pathways)
By [HealthVerity](https://blog.healthverity.com/author/healthverity) 18 September 2025
Turning claims into interoperable evidence More means more. In a world where anyone can make...
[READ MORE](https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough)
[](https://blog.healthverity.com/measuring-cost-savings-of-virtual-pt-with-healthverity-marketplace-closed-claims)
#### [Measuring cost savings of virtual PT with HealthVerity Marketplace closed claims](https://blog.healthverity.com/measuring-cost-savings-of-virtual-pt-with-healthverity-marketplace-closed-claims)
By [HealthVerity](https://blog.healthverity.com/author/healthverity) 2 September 2025
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
[READ MORE](https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough)
[](https://blog.healthverity.com/veterans-day-at-healthverity-two-paths-from-service-to-impact)
#### [Veterans Day at HealthVerity: Two paths from service to impact](https://blog.healthverity.com/veterans-day-at-healthverity-two-paths-from-service-to-impact)
By [HealthVerity](https://blog.healthverity.com/author/healthverity) 11 November 2025
Veterans Day invites us to look beyond branch and rank to the people and stories behind the...
[READ MORE](https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough)
#### Who we serve
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Government](https://healthverity.com/government/)
- [Insurance](https://healthverity.com/insurance/)
- [Channel Partners](https://healthverity.com/channel-partners/)
- [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
#### How we help
- [HealthVerity Marketplace](https://healthverity.com/marketplace/)
- [HealthVerity Mastersets](https://healthverity.com/mastersets/)
- [HealthVerity FLOW](https://healthverity.com/flow/)
- [The IPGE Approach](https://healthverity.com/ipge-approach/)
#### Resources
- [HealthVerity Blog](https://blog.healthverity.com/)
- [News & Events](https://healthverity.com/resources/news-and-events/)
- [Resource Library](https://healthverity.com/resources/resource-library/)
- [Publications](https://healthverity.com/resources/publications/)
#### Our company
- [About Us](https://healthverity.com/about-us/)
- [Leadership](https://healthverity.com/about-us/#leadership)
- [Board of Directors](https://healthverity.com/about-us/#board)
- [Careers](https://healthverity.com/careers/)
- [Contact](https://healthverity.com/contact/)
©2026 HealthVerity, Inc. | [Terms & Conditions](https://healthverity.com/terms-and-conditions/) | [Privacy Policy](https://healthverity.com/privacy-policy/)
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Organization",
"name" : "HealthVerity"
},
"datePublished" : "2026-09-02",
"description" : "Discover why relying solely on billed and allowed amounts in medical claims data creates blind spots in healthcare analytics. Learn how analyzing actual remitted amounts provides a truer picture of market access and payer behavior.",
"headline" : "When billed and allowed amounts aren't enough",
"keywords" : [ "billed vs allowed amounts", "remitted amounts healthcare", "medical claims data analytics", "healthcare pricing transparency", "payer reimbursement rates", "market access strategy", "HEOR data", "healthcare economics" ],
"mainEntityOfPage" : {
"@id" : "https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://healthverity.com/wp-content/uploads/2023/08/healthverity-logo.png"
},
"name" : "HealthVerity"
}
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "FAQPage",
"mainEntity" : [ {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "The 'billed amount' is the gross charge a provider asks for (sticker price). The 'allowed amount' is the maximum price an insurer agrees to recognize based on their contract. The 'remitted amount' (or paid amount) is the actual cash flow—the final amount the payer actually transfers to the provider after factoring in patient deductibles, copays, and secondary insurance."
},
"name" : "What is the difference between billed, allowed, and remitted amounts in healthcare?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Relying only on billed and allowed amounts creates an incomplete financial picture. Allowed amounts indicate a contractual ceiling, but they don't reflect the actual cash paid by the insurer. Without knowing the remitted amount, life sciences and HEOR teams cannot accurately model out-of-pocket patient burden or true payer reimbursement behavior."
},
"name" : "Why are billed and allowed amounts insufficient for healthcare analytics?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "If a pharmaceutical company cannot see the actual remitted amount, they cannot accurately assess how a drug is performing on a formulary. A payer might have a favorable 'allowed' amount on paper, but if the actual remitted amounts are low due to high patient deductibles, patient adherence and access will drop."
},
"name" : "How does missing remitted data impact market access strategies?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Understanding the gap between the allowed amount and the remitted amount reveals the patient's out-of-pocket responsibility. High out-of-pocket costs are the leading cause of prescription abandonment. Tracking this data helps manufacturers optimize copay assistance programs and pricing strategies."
},
"name" : "Why is patient out-of-pocket data critical for pricing analysis?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Advanced real-world data platforms integrate comprehensive closed claims data, which includes the final adjudicated financial details—including the exact remitted amounts. This allows organizations to move beyond estimated 'sticker prices' and base their analytics on actual healthcare financial transactions."
},
"name" : "How can real-world data (RWD) solve healthcare pricing blind spots?"
} ]
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BreadcrumbList",
"itemListElement" : [ {
"@type" : "ListItem",
"item" : "https://healthverity.com/",
"name" : "Home",
"position" : 1
}, {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/",
"name" : "Blog",
"position" : 2
}, {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough",
"name" : "When billed and allowed amounts aren't enough",
"position" : 3
} ]
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"articleSection" : "Healthcare Data Analytics",
"author" : {
"@type" : "Organization",
"name" : "HealthVerity"
},
"dateModified" : "2026-04-22",
"datePublished" : "2026-04-22",
"description" : "Learn why traditional billed and allowed amounts can be incomplete in closed claims data and how HealthVerity’s taXonomy Market Costs provides a standardized, validated approach for more reliable real-world evidence generation.",
"headline" : "A better way to measure healthcare costs in closed claims data",
"keywords" : [ "real-world evidence", "RWE", "healthcare costs", "closed claims data", "allowed amount", "billed amount", "taXonomy", "market costs", "health economics", "claims analytics" ],
"mainEntityOfPage" : {
"@id" : "https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.healthverity.com/logo.png"
},
"name" : "HealthVerity"
}
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "FAQPage",
"mainEntity" : [ {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Billed and allowed amounts in closed claims data can be missing, inconsistent, or unevenly distributed across payer types and suppliers. These limitations reduce comparability and generalizability, making them unreliable for accurate cost analysis in real-world evidence studies."
},
"name" : "Why are billed and allowed amounts insufficient in closed claims data?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "taXonomy Market Costs is a proprietary HealthVerity methodology that generates standardized and validated cost benchmarks using remittance data for medical services and open pharmacy claims for prescriptions, providing a consistent cost signal for analysis."
},
"name" : "What are taXonomy Market Costs?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Medical market costs are derived from Electronic Remittance Advice (ERA) 835 data, capturing detailed payment exchanges between patients, payers, and providers. These values are aggregated into unit-cost benchmarks based on procedure codes, payer type, geography, and time period."
},
"name" : "How are medical market costs calculated?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Pharmacy market costs are built from open pharmacy claims and benchmarked at the base product key level, incorporating factors such as drug name, strength, quantity, payer type, geography, and year to estimate allowed and paid amounts."
},
"name" : "How are pharmacy market costs calculated?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Yes. Validation analysis showed strong agreement between market-derived and payer-derived costs, with regression results indicating near parity, supporting market costs as a reliable proxy for payer costs in real-world evidence studies."
},
"name" : "Do market costs align with payer-derived costs?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Standardized market costs improve study feasibility, comparability, and reproducibility by providing consistent and comprehensive cost measures, even when traditional cost fields are missing or incomplete."
},
"name" : "Why are standardized market costs important for RWE studies?"
} ]
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BreadcrumbList",
"itemListElement" : [ {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/",
"name" : "Blog",
"position" : 1
}, {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/when-billed-and-allowed-amounts-arent-enough",
"name" : "When billed and allowed amounts aren't enough",
"position" : 2
} ]
}
```